Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.62 |
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | GSK3A | P49840 | 3/20 | 0.62 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.62 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.62 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.62 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laduviglusib SCHEMBL240280 | 0.90 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Laduviglusib SCHEMBL29838591 | 0.90 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Laduviglusib SCHEMBL29381114 | 0.90 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Laduviglusib SCHEMBL17165152 | 0.89 | GSK3B (0.76) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL5094723 | 0.84 | GSK3B (0.66) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL12552315 | 0.83 | GSK3B (0.67) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL4398952 | 0.81 | GSK3B (0.65) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL20095066 | 0.81 | GSK3B (0.72) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL23180940 | 0.80 | GSK3B (0.57) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL4404427 | 0.80 | GSK3B (0.64) | GSK3BCDK1GSK3ACCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133499-A1 | Development of Combined Therapeutic Agent for Fibrotic Disease | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20230133499-A1 | Development of Combined Therapeutic Agent for Fibrotic Disease | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133499-A1 | Development of Combined Therapeutic Agent for Fibrotic Disease | COL2A1, COL1A1, MMP1 | GSK3B 83/4885CDK1 1625/4885GSK3A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.